First Thing, Daily Maverick's flagship newsletter

Join the 230 000 South Africans who read First Thing newsletter.

We'd like our readers to start paying for Daily Maverick

More specifically, we'd like those who can afford to pay to start paying. What it comes down to is whether or not you value Daily Maverick. Think of us in terms of your daily cappuccino from your favourite coffee shop. It costs around R35. That’s R1,050 per month on frothy milk. Don’t get us wrong, we’re almost exclusively fuelled by coffee. BUT maybe R200 of that R1,050 could go to the journalism that’s fighting for the country?

We don’t dictate how much we’d like our readers to contribute. After all, how much you value our work is subjective (and frankly, every amount helps). At R200, you get it back in Uber Eats and ride vouchers every month, but that’s just a suggestion. A little less than a week’s worth of cappuccinos.

We can't survive on hope and our own determination. Our country is going to be considerably worse off if we don’t have a strong, sustainable news media. If you’re rejigging your budgets, and it comes to choosing between frothy milk and Daily Maverick, we hope you might reconsider that cappuccino.

We need your help. And we’re not ashamed to ask for it.

Our mission is to Defend Truth. Join Maverick Insider.

Support Daily Maverick→
Payment options

Britain lines up more potential COVID-19 vaccine suppli...



Britain lines up more potential COVID-19 vaccine supplies with J&J, Novavax deals

epa08534376 Novavax Inc. headquarters in Gaithersburg, Maryland, USA, 08 July 2020. The company received a 1.6 billion US dollar award from the US government to further develop its experimental COVID-19 vaccine. EPA-EFE/JIM LO SCALZO
By Reuters
14 Aug 2020 0

LONDON, Aug 14 (Reuters) - Britain will buy potential COVID-19 vaccines from U.S. drugmakers Johnson & Johnson and Novavax Inc, the companies said on Friday, boosting the number of deals it has with drugmakers as the global vaccine race rages on.

Britain and the United States are in the lead with six vaccine deals with drugmakers each, as companies and governments worldwide work overtime to find a vaccine against the global pandemic.

The latest agreements bring Britain’s total number of doses secured to 362 million for a population of 66 million.

The deals cover a wide range of vaccine types currently in development for COVID-19, as Britain seeks to hedge its bets should one or more of the technologies prove ineffective.

Johnson & Johnson said its Janssen Pharmaceutica unit will supply the British government with its candidate known as Ad26.COV2.S with an initial sale of 30 million doses on a not-for-profit basis for emergency pandemic use.

The advance purchase agreement will also provide an option for an additional purchase of up to a 22 million doses, it said.

In a separate statement, Novavax said Britain would buy 60 million doses of its coronavirus vaccine candidate, NVX-CoV2373, for a phase 3 clinical trial.

The Janssen vaccine uses an adenovirus technique to ferry coronavirus proteins into cells in the body, while the Novavax shot uses a technology known as recombinant nanoparticle to produce antigens – molecules that are designed to spur the immune system into action.

Kate Bingham, chair of the UK Vaccine Taskforce, said that choosing vaccines that use different approaches maximised the chances of success.

“We have now assembled our core portfolio of different vaccines, because we don’t know if any of these different vaccines will work,” Bingham told Sky News.

Recent studies suggest that the odds of an experimental vaccine making it from early testing in people to regulatory approval are roughly one in three.

J&J said it has also agreed to collaborate with the British government on a global Phase III trial to explore the two-dose regimen of its vaccine candidate.

It will run parallel to the Phase III trial investigating the single-dose programme.

No vaccine has yet proven to work, but more than 20 candidates are in clinical trials. (Reporting by Alistair Smout and Josephine Mason; editing by Jan Harvey, Jason Neely and Ana Nicolaci da Costa)


"Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]"

Please peer review 3 community comments before your comment can be posted